Oncology | Phase II Developments | NORWAY

BerGenBio ASA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib in Combination With Keytruda® in NSCLC Patients

Lead Product(s): Bemcentinib,Pembrolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 15, 2020

Details:

The presentation to be given will provide an update of results from a phase II trial, evaluating bemcentinib in combination with MSD’s Keytruda in previously treated non-small cell lung cancer (NSCLC) patients.

Nordic Nanovector

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021

Lead Product(s): Lutetium (177Lu)-lilotomab satetraxetan

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

Streamlined strategy with all resources focused on PARADIGME- all other trials to be suspended following completion of the current cohorts and all investments in pre-clinical assets to be halted.

BerGenBio ASA

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda® in NSCLC P...

Lead Product(s): Bemcentinib,Pembrolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 15, 2020

Details:

The clinical efficacy endpoint met for the Phase II trial cohort evaluating selective AXL inhibitor bemcentini- Keytruda combo, in patients with advanced NSCLC who failed checkpoint inhibitor therapy.

Find

Find Oncology Drugs in Phase II Clinical Development in NORWAY

Norway

Product Type

Companies

BerGenBio ASA

BerGenBio to Present Top Line Translational Phase II Data With Bemcentinib in Combination With Keytruda® in NSCLC Patients

Nordic Nanovector

Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021

BerGenBio ASA

BerGenBio Meets Efficacy Endpoint For First Stage Of Phase II Trial With AXL Inhibitor Bemcentinib in Combination With Keytruda® in NSCLC P...